NanoViricides FY26 net loss narrows 13% to $8.22 million; revenue remains no revenue

By Public Technologies
  • NanoViricides posted a net loss of $8.22 million for the year ended June 30, 2026, narrowing 13%.
  • Basic and diluted loss per share improved to $0.41, compared with $0.63 a year earlier.
  • Research and development expense fell 15% to $4.71 million, while general and administrative costs dropped 11% to $3.6 million.
  • It reported no revenue for the year.
  • Cash and cash equivalents were $2.8 million at June 30, 2026, and management flagged substantial doubt about going-concern funding for 12 months.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NanoViricides Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-111390), on September 28, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.